Fluarix Approved in Time for Flu Season

NOVEMBER 01, 2005
Susan Farley

The FDA approved GlaxoSmithKline's influenza vaccine, Fluarix, indicated for adults 18 years and older, following a phase 3 clinical trial. The randomized, double-blind, placebo- controlled study of approximately 1000 US adults showed Fluarix to be safe and immunogenic. Fluarix will be available to health care practitioners in prefilled Tip-Lok syringes in time for this year's flu season. John Treanor, MD, of the University of Rochester Medical Center, commented, "The introduction of Fluarix is a vital step in the effort to improve vaccination rates in the United States and protect against this highly communicable infection that threatens young and old alike." GlaxoSmithKline's Chief Executive Officer Jean-Pierre Garnier remarked, "The shortage of the flu vaccine last year was a reminder of the importance of vaccines in health care."

Ms. Farley is a freelance medical writer based in Wakefield, RI.


Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 


Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Next-Generation Pharmacist® Awards

3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference

Personalize the information you receive by selecting targeted content and special offers.